BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morgan K, Samuel K, Vandeputte M, Hayes PC, Plevris JN. SARS-CoV-2 Infection and the Liver. Pathogens. 2020;9. [PMID: 32486188 DOI: 10.3390/pathogens9060430] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Vuppalanchi V, Gelow K, Green K, Vuppalanchi R, Lammert C. Behaviors, symptoms, and outcomes of North American patients with autoimmune hepatitis during the COVID-19 pandemic. J Investig Med 2021:jim-2021-001871. [PMID: 34315800 DOI: 10.1136/jim-2021-001871] [Reference Citation Analysis]
2 Ristic-Medic D, Petrovic S, Arsic A, Vucic V. Liver disease and COVID-19: The link with oxidative stress, antioxidants and nutrition. World J Gastroenterol 2021; 27(34): 5682-5699 [PMID: 34629794 DOI: 10.3748/wjg.v27.i34.5682] [Reference Citation Analysis]
3 Wang T, Smith DA, Campbell C, Harris S, Salih H, Várnai KA, Woods K, Noble T, Freeman O, Moysova Z, Marjot T, Webb GJ, Davies J, Barnes E, Matthews PC. Longitudinal analysis of the utility of liver biochemistry in hospitalised COVID-19 patients as prognostic markers. Hepatol Commun 2021. [PMID: 34222741 DOI: 10.1002/hep4.1739] [Reference Citation Analysis]
4 Li W, Lin F, Dai M, Chen L, Han D, Cui Y, Pan P. Early predictors for mechanical ventilation in COVID-19 patients. Ther Adv Respir Dis 2020;14:1753466620963017. [PMID: 33054630 DOI: 10.1177/1753466620963017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Goh D, Lee JN, Tien T, Lim JCT, Lim S, Tan AS, Liu J, Tan B, Yeong J. Comparison between non-pulmonary and pulmonary immune responses in a HIV decedent who succumbed to COVID-19. Gut 2021:gutjnl-2021-324754. [PMID: 34376518 DOI: 10.1136/gutjnl-2021-324754] [Reference Citation Analysis]
6 Frater JL, Wang T, Lee Y. Laboratory hematologic features of COVID-19 associated liver injury: A systematic review. WJMA 2021;9:192-206. [DOI: 10.13105/wjma.v9.i2.192] [Reference Citation Analysis]
7 Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 mo of the pandemic. JHEP Rep. 2020;2:100169. [PMID: 32835190 DOI: 10.1016/j.jhepr.2020.100169] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 21.0] [Reference Citation Analysis]
8 Alroomi M, Rajan R, Alsaber A, Pan J, Abdullah M, Abdelnaby H, Aboelhassan W, AlNasrallah N, Al-Bader B, Malhas H, Ramadhan M, Hussein S, Alotaibi N, Al Saleh M, Zhanna KD, Almutairi F. In-hospital mortality in SARS-CoV-2 stratified by gamma-glutamyl transferase levels. J Clin Lab Anal 2022;:e24291. [PMID: 35261080 DOI: 10.1002/jcla.24291] [Reference Citation Analysis]
9 Luglio M, Tannuri U, de Carvalho WB, Bastos KLM, Rodriguez IS, Johnston C, Delgado AF. COVID-19 and Liver Damage: Narrative Review and Proposed Clinical Protocol for Critically ill Pediatric Patients. Clinics (Sao Paulo) 2020;75:e2250. [PMID: 33206767 DOI: 10.6061/clinics/2020/e2250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ozkurt Z, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. World J Clin Cases 2022; 10(4): 1140-1163 [DOI: 10.12998/wjcc.v10.i4.1140] [Reference Citation Analysis]
11 Zhai G, Li M, Wang Y, Wu J. Drug-Induced Liver Disturbance During the Treatment of COVID-19. Front Pharmacol 2021;12:719308. [PMID: 34483929 DOI: 10.3389/fphar.2021.719308] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Marjot T, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, Pose E, Brenner EJ, Cargill T, Catana MA, Dhanasekaran R, Eshraghian A, García-Juárez I, Gill US, Jones PD, Kennedy J, Marshall A, Matthews C, Mells G, Mercer C, Perumalswami PV, Avitabile E, Qi X, Su F, Ufere NN, Wong YJ, Zheng MH, Barnes E, Barritt AS 4th, Webb GJ. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol 2021;74:567-77. [PMID: 33035628 DOI: 10.1016/j.jhep.2020.09.024] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 34.5] [Reference Citation Analysis]
13 Dong M, Zhang J, Ma X, Tan J, Chen L, Liu S, Xin Y, Zhuang L. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomed Pharmacother 2020;131:110678. [PMID: 32861070 DOI: 10.1016/j.biopha.2020.110678] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 19.5] [Reference Citation Analysis]
14 Zeng QL, Yu ZJ, Ji F, Li GM, Zhang GF, Xu JH, Lin WB, Zhang GQ, Li GT, Cui GL, Wang FS. Dynamic changes in liver function parameters in patients with coronavirus disease 2019: a multicentre, retrospective study. BMC Infect Dis 2021;21:818. [PMID: 34399709 DOI: 10.1186/s12879-021-06572-z] [Reference Citation Analysis]
15 Frater JL, Wang T, Lee YS. Laboratory hematologic features of COVID-19 associated liver injury: A systematic review. World J Meta-Anal 2021; 9(2): 193-207 [DOI: 10.13105/wjma.v9.i2.193] [Reference Citation Analysis]
16 Bütikofer S, Lenggenhager D, Wendel Garcia PD, Maggio EM, Haberecker M, Reiner CS, Brüllmann G, Buehler PK, Gubler C, Müllhaupt B, Jüngst C, Morell B. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19. Liver Int 2021. [PMID: 34018314 DOI: 10.1111/liv.14971] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Yamazaki S, Suzuki T, Sayama M, Nakada TA, Igari H, Ishii I. Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19. J Infect Chemother 2021;27:390-2. [PMID: 33402301 DOI: 10.1016/j.jiac.2020.12.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]